A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients
- 1 March 2003
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (4) , 447-453
- https://doi.org/10.1016/s0959-8049(02)00499-9
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Value of Epidermal Growth Factor Receptor, HER2, p53, and Steroid Receptors in Predicting the Efficacy of Tamoxifen in High-Risk Postmenopausal Breast Cancer PatientsJournal of Clinical Oncology, 2001
- p53 determination alongside classical prognostic factors in node-negative breast cancer: An evaluation at more than 10-year follow-upAnnals of Oncology, 2000
- Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapyCancer, 2000
- The prognostic value of p53 and c-erb b-2 immunostaining is overrated for patients with lymph node negative breast carcinomaCancer, 2000
- TP53Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast CancerActa Oncologica, 2000
- p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.Journal of Clinical Oncology, 1998
- p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.Journal of Clinical Oncology, 1998
- bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.Journal of Clinical Oncology, 1997
- TP53 andMYC gene alterations independently predict poor prognosis in breast cancer patientsGenes, Chromosomes and Cancer, 1996
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994